Spark Therapeutics (NASDAQ:ONCE) has been assigned a $64.00 price objective by stock analysts at BMO Capital Markets in a report released on Wednesday. The brokerage currently has a “buy” rating on the biotechnology company’s stock. BMO Capital Markets’ price target would indicate a potential upside of 27.41% from the company’s current price.
ONCE has been the topic of a number of other reports. Raymond James Financial restated a “buy” rating and issued a $75.00 price target on shares of Spark Therapeutics in a research note on Thursday, December 7th. Barclays restated a “buy” rating and issued a $54.00 price target on shares of Spark Therapeutics in a research note on Wednesday, December 13th. Cantor Fitzgerald set a $105.00 price target on Spark Therapeutics and gave the company a “buy” rating in a research note on Wednesday, January 3rd. ValuEngine downgraded Spark Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Friday, February 2nd. Finally, Wedbush upgraded Spark Therapeutics from an “underperform” rating to a “neutral” rating and decreased their price target for the company from $65.00 to $50.00 in a research note on Tuesday, December 12th. They noted that the move was a valuation call. Two investment analysts have rated the stock with a sell rating, five have given a hold rating and seventeen have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $69.88.
Spark Therapeutics (ONCE) traded down $4.27 during trading on Wednesday, hitting $50.23. The company had a trading volume of 1,442,600 shares, compared to its average volume of 751,164. Spark Therapeutics has a 12-month low of $41.06 and a 12-month high of $91.75. The stock has a market capitalization of $2,016.80, a P/E ratio of -7.03 and a beta of 3.02.
Spark Therapeutics (NASDAQ:ONCE) last posted its quarterly earnings results on Tuesday, February 20th. The biotechnology company reported ($1.73) earnings per share for the quarter, meeting the Zacks’ consensus estimate of ($1.73). Spark Therapeutics had a negative return on equity of 60.01% and a negative net margin of 1,090.11%. The firm had revenue of $7.41 million for the quarter, compared to the consensus estimate of $9.53 million. research analysts predict that Spark Therapeutics will post -7.55 earnings per share for the current fiscal year.
In other Spark Therapeutics news, insider Katherine A. High sold 5,000 shares of the business’s stock in a transaction on Tuesday, November 28th. The stock was sold at an average price of $71.32, for a total transaction of $356,600.00. Following the sale, the insider now directly owns 215,000 shares in the company, valued at $15,333,800. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 7.30% of the stock is currently owned by insiders.
A number of institutional investors and hedge funds have recently bought and sold shares of the business. BlackRock Inc. boosted its position in Spark Therapeutics by 1.4% during the fourth quarter. BlackRock Inc. now owns 2,650,258 shares of the biotechnology company’s stock worth $136,277,000 after purchasing an additional 35,801 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of Spark Therapeutics by 5.3% in the second quarter. Vanguard Group Inc. now owns 1,924,463 shares of the biotechnology company’s stock valued at $114,968,000 after acquiring an additional 96,803 shares in the last quarter. JPMorgan Chase & Co. lifted its position in shares of Spark Therapeutics by 15.0% in the third quarter. JPMorgan Chase & Co. now owns 1,848,988 shares of the biotechnology company’s stock valued at $164,986,000 after acquiring an additional 241,016 shares in the last quarter. Janus Henderson Group PLC lifted its position in shares of Spark Therapeutics by 46.4% in the third quarter. Janus Henderson Group PLC now owns 756,088 shares of the biotechnology company’s stock valued at $67,413,000 after acquiring an additional 239,723 shares in the last quarter. Finally, Clearbridge Investments LLC lifted its position in shares of Spark Therapeutics by 2.9% in the fourth quarter. Clearbridge Investments LLC now owns 687,444 shares of the biotechnology company’s stock valued at $35,348,000 after acquiring an additional 19,492 shares in the last quarter.
ILLEGAL ACTIVITY WARNING: This story was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this story on another domain, it was illegally copied and republished in violation of US and international copyright and trademark law. The legal version of this story can be accessed at https://www.dispatchtribunal.com/2018/02/21/spark-therapeutics-once-pt-set-at-64-00-by-bmo-capital-markets.html.
About Spark Therapeutics
Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.
Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.